Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 135

Similar articles for PubMed (Select 23621904)

1.

Virulence of pertactin-negative Bordetella pertussis isolates from infants, France.

Bodilis H, Guiso N.

Emerg Infect Dis. 2013 Mar;19(3):471-4. doi: 10.3201/1903.121475.

2.

Rapid increase in pertactin-deficient Bordetella pertussis isolates, Australia.

Lam C, Octavia S, Ricafort L, Sintchenko V, Gilbert GL, Wood N, McIntyre P, Marshall H, Guiso N, Keil AD, Lawrence A, Robson J, Hogg G, Lan R.

Emerg Infect Dis. 2014 Apr;20(4):626-33. doi: 10.3201/eid2004.131478.

3.

Evolution of French Bordetella pertussis and Bordetella parapertussis isolates: increase of Bordetellae not expressing pertactin.

Hegerle N, Paris AS, Brun D, Dore G, Njamkepo E, Guillot S, Guiso N.

Clin Microbiol Infect. 2012 Sep;18(9):E340-6. doi: 10.1111/j.1469-0691.2012.03925.x. Epub 2012 Jun 21.

4.

Bordetella pertussis and pertactin-deficient clinical isolates: lessons for pertussis vaccines.

Hegerle N, Guiso N.

Expert Rev Vaccines. 2014 Sep;13(9):1135-46. doi: 10.1586/14760584.2014.932254. Epub 2014 Jun 23. Review.

PMID:
24953157
5.

Pertactin-negative variants of Bordetella pertussis in New York State: a retrospective analysis, 2004-2013.

Quinlan T, Musser KA, Currenti SA, Zansky SM, Halse TA.

Mol Cell Probes. 2014 Aug;28(4):138-40. doi: 10.1016/j.mcp.2013.12.003. Epub 2013 Dec 21.

PMID:
24365130
7.

A natural pertactin deficient strain of Bordetella pertussis shows improved entry in human monocyte-derived dendritic cells.

Stefanelli P, Fazio C, Fedele G, Spensieri F, Ausiello CM, Mastrantonio P.

New Microbiol. 2009 Apr;32(2):159-66.

8.

Investigations into the emergence of pertactin-deficient Bordetella pertussis isolates in six European countries, 1996 to 2012.

Zeddeman A, van Gent M, Heuvelman CJ, van der Heide HG, Bart MJ, Advani A, Hallander HO, Wirsing von Konig CH, Riffelman M, Storsaeter J, Vestrheim DF, Dalby T, Krogfelt KA, Fry NK, Barkoff AM, Mertsola J, He Q, Mooi F.

Euro Surveill. 2014 Aug 21;19(33). pii: 20881.

9.

Prevalence and molecular characterization of pertactin-deficient Bordetella pertussis in the United States.

Pawloski LC, Queenan AM, Cassiday PK, Lynch AS, Harrison MJ, Shang W, Williams MM, Bowden KE, Burgos-Rivera B, Qin X, Messonnier N, Tondella ML.

Clin Vaccine Immunol. 2014 Feb;21(2):119-25. doi: 10.1128/CVI.00717-13. Epub 2013 Nov 20.

10.

First report and detailed characterization of B. pertussis isolates not expressing Pertussis Toxin or Pertactin.

Bouchez V, Brun D, Cantinelli T, Dore G, Njamkepo E, Guiso N.

Vaccine. 2009 Oct 9;27(43):6034-41. doi: 10.1016/j.vaccine.2009.07.074. Epub 2009 Aug 8.

PMID:
19666155
11.

Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom.

Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC.

Infect Immun. 2001 Sep;69(9):5520-8. Erratum in: Infect Immun 2001 Oct;69(10):6564.

12.

Acellular vaccines induce cell-mediated immunity to Bordetella pertussis antigens in infants undergoing primary vaccination against pertussis.

Ausiello CM, Urbani F, La Sala A, Lande R, Piscitelli A, Cassone A.

Dev Biol Stand. 1997;89:315-20.

PMID:
9272365
13.

Shifts of Bordetella pertussis variants in Sweden from 1970 to 2003, during three periods marked by different vaccination programs.

Hallander HO, Advani A, Donnelly D, Gustafsson L, Carlsson RM.

J Clin Microbiol. 2005 Jun;43(6):2856-65.

14.
15.

Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children.

Mastrantonio P, Spigaglia P, van Oirschot H, van der Heide HG, Heuvelman K, Stefanelli P, Mooi FR.

Microbiology. 1999 Aug;145 ( Pt 8):2069-75.

16.

Acellular pertussis vaccines and the role of pertactin and fimbriae.

Poolman JT, Hallander HO.

Expert Rev Vaccines. 2007 Feb;6(1):47-56. Review.

PMID:
17280478
17.

Pulsed-field gel electrophoresis, pertactin, pertussis toxin S1 subunit polymorphisms, and surfaceome analysis of vaccine and clinical Bordetella pertussis strains.

Bottero D, Gaillard ME, Fingermann M, Weltman G, Fernández J, Sisti F, Graieb A, Roberts R, Rico O, Ríos G, Regueira M, Binsztein N, Hozbor D.

Clin Vaccine Immunol. 2007 Nov;14(11):1490-8. Epub 2007 Aug 15.

18.

Synergic effect of genotype changes in pertussis toxin and pertactin on adaptation to an acellular pertussis vaccine in the murine intranasal challenge model.

Komatsu E, Yamaguchi F, Abe A, Weiss AA, Watanabe M.

Clin Vaccine Immunol. 2010 May;17(5):807-12. doi: 10.1128/CVI.00449-09. Epub 2010 Mar 31.

19.

Whooping cough in South-East Romania: a 1-year study.

Dinu S, Guillot S, Dragomirescu CC, Brun D, Lazăr S, Vancea G, Ionescu BM, Gherman MF, Bjerkestrand AF, Ungureanu V, Guiso N, Damian M.

Diagn Microbiol Infect Dis. 2014 Mar;78(3):302-6. doi: 10.1016/j.diagmicrobio.2013.09.017. Epub 2013 Nov 26.

PMID:
24355701
20.

Molecular aspects of Bordetella pertussis pathogenesis.

Locht C.

Int Microbiol. 1999 Sep;2(3):137-44. Review.

PMID:
10943406
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk